Marketing Communications – US
Marketing Communications – US
Life Molecular Imaging (LMI) is a global, innovative company focusing on the development and commercialization of molecular imaging radiopharmaceuticals for our approved F-18 amyloid PET tracer Neuraceq® and a pipeline of PET tracers in clinical development. LMI continues to grow at a steady pace creating the need for the following full-time position:
Marketing Communications (Marcom) will be responsible for the development and execution of the tactical elements of the North American Neuraceq® brand strategy, digital marketing campaign, social media platform, and responsible for the communication plans to support Life Molecular Imaging pipeline compounds. The US team is 100% home-based, but you will be required to travel up to 25% of the time This position will work with other team members across the US and Globally and therefore, you must be flexible to work outside the normal business hours when needed to support other time zones. This position would ideally be located in the Eastern or Central Time Zones.
Key Tasks and Responsibilities:
What we expect:
To be successful in this role, you will have proven experience in superior interpersonal and verbal/written communication skills. Have an established track record of experience in building and leading a digital marketing campaign for brand awareness. Advanced knowledge of Microsoft Office products and other marketing software. Bachelor’s degree in relevant field and three-five years of work experience in a biopharma or brand marketing role. Further direct experience will be considered in lieu of education. Ability to prioritize tasks and meet goals within deadlines. We are looking for people who are just as passionate as we are to improving the lives of those with Alzheimer’s and other neurodegenerative diseases and are excited to work for a growing company.
What you can expect:
LMI will provide the technology and training needed along with the support of coworkers, managers, and other divisions of the company. You will be able to make significant contributions through your expertise. You can expect what YOU do to matter. All our employees are an integral part of a global organization, as well as the people and communities we serve.
Life Molecular Imaging, Inc. is an Equal Opportunity Employer. We believe what we do and our culture of “More Than a Job. It’s Making Life Better” extends to creating a welcoming, safe, and inclusive work environment. If you have what it takes and the passion to make a difference, please visit our website to learn more. www.life-mi.com
Please send any inquiries, or submit cover letter with resume to: firstname.lastname@example.org
PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.
Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.
SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program